Replies to post #365742 on Amarin Corp Plc (AMRN)

[Number sleven]

Raf, Thanks for the numbers. DRL had a tough week. I wonder if the generic companies have now hit the ceiling of supply from CCSB? If anybody finds information on where Apotex gets API, it would be good to know.
Sleven,

[invest2992]

thanx rafun

[BioBull]

Lowest number of new scripts since 1/3/20.

[rafunrafun]

Scripts for week ending January 7, 2022

Drug Industry TRx: +8.3% w/w

Vascepa
TRx 70,886; -1.6% (-1,137) w/w; -17.5% y/y
NRx 31,441; +5.9% (+1,739) w/w; -19.1% y/y
Ref 39,444; -6.8% (-2,875) w/w; -16.1% y/y

Lovaza (Generic & Brand)
TRx 59,869; +3.9% (+2,245) w/w; -6.0% y/y
NRx 30,119; +12.7% (+3,400) w/w; -5.7% y/y
Ref 29,750; -3.7% (-1,156) w/w; -6.2% y/y

Generic Vascepa
TRx 22,983; +1.5% (+341) w/w; As % of total V: 24.5%
NRx 12,997; +7.5% (+908) w/w; As % of total V: 29.2%
Ref 9,986; -5.4% (-567) w/w; As % of total V: 20.2%

Generic Vascepa by Manufacturer
Hikma - TRx 11,375 (-559); Generic share 49.5%; Total V share 12.1%
Reddy - TRx 11,577 (+873); Generic share 50.4%; Total V share 12.3%
Apotex - TRx 32 (+29); Generic share 0.1%; Total V share 0%

Vascepa + Generic Vascepa
TRx 93,869; -0.8% (-795) w/w; +2.8% y/y
NRx 44,438; +6.3% (+2,647) w/w; +6.3% y/y
Ref 49,431; -6.5% (-3,442) w/w; -0.2% y/y